[go: up one dir, main page]

EP2144871B1 - Amidation process for the preparation of cathepsin k inhibitors - Google Patents

Amidation process for the preparation of cathepsin k inhibitors Download PDF

Info

Publication number
EP2144871B1
EP2144871B1 EP08733702.8A EP08733702A EP2144871B1 EP 2144871 B1 EP2144871 B1 EP 2144871B1 EP 08733702 A EP08733702 A EP 08733702A EP 2144871 B1 EP2144871 B1 EP 2144871B1
Authority
EP
European Patent Office
Prior art keywords
batch
water
base
solvent
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP08733702.8A
Other languages
German (de)
French (fr)
Other versions
EP2144871A1 (en
EP2144871A4 (en
Inventor
Paul O'shea
Francis Gosselin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Publication of EP2144871A1 publication Critical patent/EP2144871A1/en
Publication of EP2144871A4 publication Critical patent/EP2144871A4/en
Application granted granted Critical
Publication of EP2144871B1 publication Critical patent/EP2144871B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Definitions

  • This invention describes an amidation process whereby perfluorinated amino acids can be activated and treated with an amine in the presence of a base to yield amides, without loss of optical purity.
  • the resulting amides are selective cathepsin K inhibitors which can be used in the treatment of osteoporosis and metastatic bone disease.
  • WO-A-2006034004 (Axys Pharmaceuticals, Inc.) discloses making deoxy-odanacatib through the conversion of an acid via an activated acid and reaction with an aminocarbonitrile into the final compound.
  • EDC is given as an example of a coupling agent.
  • WO-A-2005021487 and WO-A-2005019161 disclose processes which first form N-1-(4-bromophenyl)-ethyl-leucinamide derivatives using DIPEA, HOBt and TOTU as coupling reagents, followed by replacing the bromine with a methylthio group.
  • WO-A-2003075836 (Merck Frosst Canada and Axys Pharmaceuticals, Inc.) discloses a process using HATU as coupling agent.
  • processes for the preparation of compounds of structural formula I comprising amidating a salt of formula IIA or an acid of formula IIB with 1-aminocyclopropane carbonitrile, in the presence of a coupling agent which is EDC, a base and a solvent; wherein R 1 is (2-fluoro,2-methyl)propyl; R2 is trifluoromethyl; R3 is SO 2 CH 3 ; X is a tertiary amine, a secondary amine or a metal salt; and m is an integer from zero to two.
  • a coupling agent which is EDC, a base and a solvent
  • X is a secondary amine.
  • X is DCHA.
  • the compound of formula I is N 1 -(1-cyanocyclopropyl)-4-fluoro- N 2 - ⁇ (1 S )-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl ⁇ -L-leucinamide.
  • An ⁇ -aminoacid or its corresponding salt is activated, followed by treatment with an amine in the presence of a base.
  • Activation may be achieved by formation of an acyl halide, mixed anhydride or by treatment with a coupling agent, with or without an additional activating agent, in the presence of a suitable base and in a suitable solvent.
  • the activating agent is HOBt, N -hydroxy succinimide, 2-hydroxypyridine, N -hydroxyphthalimide or CDI. In a class of the invention, the activating agent is HOBt.
  • the base is N -methyl morpholine, TEA, N- ethyldiisopropylamine, 2,6-lutidine, 2,4,6 collidine or 1-methylpiperidine.
  • the base is N -methyl morpholine.
  • the solvent is DMF, DMAc, NMP, acetonitrile, THF, or DMSO.
  • the solvent is DMF.
  • a compound of structural formula: comprising amidating a salt: with 1-aminocyclopropane carbonitrile, in the presence of EDC, HOBt, N -methyl morpholine and DMF.
  • tertiary amine includes, but is not limited to, trimethylamine, triethylamine, tripropylamine, dimethylethanolamine and bis-tris.
  • second amine includes, but is not limited to, dimethyl amine, diethylamine, methylethanolamine, aziridine, azetidine, pyrrolidine, piperidine, and dicyclohexylamine (DCHA).
  • metal salt includes, but is not limited to, salts of aluminum, antimony, calcium, copper, gold, iron, lead, lithium, magnesium, platinum, potassium, sodium, silver, strontium, tin, titanium, tungsten and zinc.
  • Preferred metal salts include salts of lithium, sodium, potassium, magnesium, calcium, aluminum and zinc.
  • carbodiimide refers to a class of coupling agents that are often used to activate carboxylic acids towards amide formation.
  • Nonlimiting examples or carbodiimides include: DCC (N,N'-dicyclohexylcarbodiimide), DIC (N,N'-diisopropylcarbodiimide) and EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride).
  • Crystalline N 1 -(1-cyanocyclopropyl)-4-fluoro- N 2 - ⁇ (1 S )-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl ⁇ -L-leucinamide is characterized by an X-ray powder diffraction (XRPD) pattern, collected using copper K ⁇ radiation, corresponding to characteristic reflection peaks at 19.7. 20.1 and 17.6 degrees. The pattern is further characterized by characteristic reflection peaks at 23.6,17.9 and 19.1 degrees. The pattern is further characterized by characteristic reflection peaks at 24.8, 11.7 and 11.9 degrees.
  • XRPD X-ray powder diffraction
  • the XRPD patterns are measured using a Scintag XDS-2000, Si(Li) Peltier-cooled solid state detector, CuKa source at a generator power of 45 kV and 40 mA, and divergent beam (2 mm and 4 mm) and receiving beam slits (0.5 mm and 0.2 mm).
  • Scan range is set from 2-40°2 ⁇ with a step size of 0.02° and a count time of 2 seconds.
  • the sample is measured on a quartz disk with spinning to reduce potential in-plane orientation effects. Peak positions are verified weekly using a standard corundum plate (NIST SRM 1976).
  • crystalline N 1 -(1-cyanocyclopropyl)-4-fluoro- N 2 - ⁇ (1 S )-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl ⁇ -L-leucinamide is characterized by melting onset at 214°C.
  • Amorphous N 1 -(1-cyanocyclopropyl)-4-fluoro- N 2 - ⁇ (1 S )-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl ⁇ -L-leucinamide can also be observed.
  • Scheme 1 depicts the reaction of a substituted ⁇ -amino acid or its salt with an amine in the presence of a coupling agent, an activator and a base to yield the corresponding ⁇ -amino amide product without epimerization of the ⁇ -stereocenter.
  • Biphenyl acid (20.74 g) was dissolved in 2-propanol (186 mL) / water (20.7 mL).
  • DCHA salt (10 mg)
  • a heavy seed bed formed and the slurry was let stir at rt for 30 min. Addition of DCHA was continued over 20-30 min. The slurry was let stir at rt overnight and filtered.
  • the filter cake was washed with 2-propanol / water (2 ⁇ 30 mL, 10:1) and MTBE (2 ⁇ 30 mL).
  • the batch was then heated to 58-62°C and aged for 1 hour. Following age, water (375 g) was charged over 3 hours, at a rate of 2.1 g/min. The batch was then cooled to 15-25°C and aged overnight. The batch was filtered and washed with 39% DMF in water (2 ⁇ 300 g) and 2-propanol (180 g). The solids were dried in the filter at 40-60°C for 24 hours. The desired crude product was isolated as a white solid (57g, 92% yield, 99.4 wt%). A round-bottom flask was charged with crude solid (57 g) and acetone/water solution (324 g, 88/12).
  • the slurry was then heated to 40°C, at which point the batch was in solution, and aged for an hour. Water (46 g) was then charged over 30 minutes. The batch was then seeded (1.7 g, 3.0 wt%), and the batch was aged at 40°C for an hour prior to proceeding with the crystallization. Water (255 g) was charged over 4.5 h. The batch was then cooled to 23°C over 1.5 h, aged for 4 h and filtered. The solids were washed with acetone/water (158 g, 45/55) and water (176 g). The filter cake was dried with nitrogen sweep / vacuum at 55°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Description

    BACKGROUND OF THE INVENTION
  • This invention describes an amidation process whereby perfluorinated amino acids can be activated and treated with an amine in the presence of a base to yield amides, without loss of optical purity. The resulting amides are selective cathepsin K inhibitors which can be used in the treatment of osteoporosis and metastatic bone disease.
  • WO-A-2006034004 (Axys Pharmaceuticals, Inc.) discloses making deoxy-odanacatib through the conversion of an acid via an activated acid and reaction with an aminocarbonitrile into the final compound. EDC is given as an example of a coupling agent.
  • WO-A-2005021487 and WO-A-2005019161 (both to Merck Frosst Canada & Co.) disclose processes which first form N-1-(4-bromophenyl)-ethyl-leucinamide derivatives using DIPEA, HOBt and TOTU as coupling reagents, followed by replacing the bromine with a methylthio group.
  • WO-A-2003075836 (Merck Frosst Canada and Axys Pharmaceuticals, Inc.) discloses a process using HATU as coupling agent.
  • SUMMARY OF THE INVENTION
  • By this invention, there are provided processes for the preparation of compounds of structural formula I:
    Figure imgb0001
    comprising amidating a salt of formula IIA or an acid of formula IIB
    Figure imgb0002
    with 1-aminocyclopropane carbonitrile, in the presence of a coupling agent which is EDC, a base and a solvent;
    wherein R1 is (2-fluoro,2-methyl)propyl;
    R2 is trifluoromethyl;
    R3 is SO2CH3;
    X is a tertiary amine, a secondary amine or a metal salt; and
    m is an integer from zero to two.
  • BRIEF DESCRIPTION OF THE DRAWINGS
    • FIGURE 1 is a characteristic X-ray diffraction pattern of crystalline N 1-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide.
    • FIGURE 2 is a typical differential scanning calorimetry (DSC) curve of crystalline N 1-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide.
    • FIGURE 3 is a typical differential scanning calorimetry (DSC) curve of amorphous N 1-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide.
    DETAILED DESCRIPTION OF THE INVENTION
  • In an embodiment of the invention X is a secondary amine. In a class of the invention, X is DCHA.
  • The compound of formula I is
    Figure imgb0003
    N 1-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide.
  • An α-aminoacid or its corresponding salt is activated, followed by treatment with an amine in the presence of a base. Activation may be achieved by formation of an acyl halide, mixed anhydride or by treatment with a coupling agent, with or without an additional activating agent, in the presence of a suitable base and in a suitable solvent.
  • In an embodiment of the invention, the activating agent is HOBt, N-hydroxy succinimide, 2-hydroxypyridine, N-hydroxyphthalimide or CDI. In a class of the invention, the activating agent is HOBt.
  • In an embodiment of the invention, the base is N-methyl morpholine, TEA, N-ethyldiisopropylamine, 2,6-lutidine, 2,4,6 collidine or 1-methylpiperidine. In a class of the invention, the base is N-methyl morpholine.
  • In an embodiment of the invention, the solvent is DMF, DMAc, NMP, acetonitrile, THF, or DMSO. In a class of the invention, the solvent is DMF.
  • In an embodiment of the invention is the process for the preparation of a compound of structural formula:
    Figure imgb0004
    comprising amidating a salt:
    Figure imgb0005
    with 1-aminocyclopropane carbonitrile, in the presence of EDC, HOBt, N-methyl morpholine and DMF.
  • The term "tertiary amine" includes, but is not limited to, trimethylamine, triethylamine, tripropylamine, dimethylethanolamine and bis-tris.
  • The term "secondary amine" includes, but is not limited to, dimethyl amine, diethylamine, methylethanolamine, aziridine, azetidine, pyrrolidine, piperidine, and dicyclohexylamine (DCHA).
  • The term "metal salt" includes, but is not limited to, salts of aluminum, antimony, calcium, copper, gold, iron, lead, lithium, magnesium, platinum, potassium, sodium, silver, strontium, tin, titanium, tungsten and zinc. Preferred metal salts include salts of lithium, sodium, potassium, magnesium, calcium, aluminum and zinc.
  • The term carbodiimide refers to a class of coupling agents that are often used to activate carboxylic acids towards amide formation. Nonlimiting examples or carbodiimides include: DCC (N,N'-dicyclohexylcarbodiimide), DIC (N,N'-diisopropylcarbodiimide) and EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride).
  • Crystalline N 1-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide is characterized by an X-ray powder diffraction (XRPD) pattern, collected using copper Kα radiation, corresponding to characteristic reflection peaks at 19.7. 20.1 and 17.6 degrees. The pattern is further characterized by characteristic reflection peaks at 23.6,17.9 and 19.1 degrees. The pattern is further characterized by characteristic reflection peaks at 24.8, 11.7 and 11.9 degrees. The XRPD patterns are measured using a Scintag XDS-2000, Si(Li) Peltier-cooled solid state detector, CuKa source at a generator power of 45 kV and 40 mA, and divergent beam (2 mm and 4 mm) and receiving beam slits (0.5 mm and 0.2 mm). Scan range is set from 2-40°2θ with a step size of 0.02° and a count time of 2 seconds. The sample is measured on a quartz disk with spinning to reduce potential in-plane orientation effects. Peak positions are verified weekly using a standard corundum plate (NIST SRM 1976).
  • In addition to the X-ray powder diffraction pattern described above, crystalline N 1-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide is characterized by melting onset at 214°C. The DSC thermal behaviour is investigated using a Seiko robotic DSC (RDC-220). DSC analyses (n=2) are carried out in crimped aluminium pans (2, 10, and 20°C/min, 80mL/min nitrogen). The DSC is calibrated for temperature and heat flow with gallium (Goodfellow, 99.99% Pure), indium (Goodfellow, 99.999% Pure), and tin (NIST SRM 2220).
  • Amorphous N 1-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide can also be observed. The glass transition temperature for the amorphous form is evaluated by temperature cycling and is measured at the mid-point. The sample are heated from -30°C to 75°C at 10°C/min following by cooling at 10°C/min to -30°C, and then the sample is re-heated to 180°C at 10°C/min (n=1). A glass transition temperature (Tg) of about 64°C (mid-point, 10°C/min) followed by an exothermic transition at a peak temperature of 101°C, attributed to recrystallization of amorphous material, is obtained for a predominantly amorphous sample. The DSC thermal behaviour is investigated using a Seiko robotic DSC (RDC-220). DSC analyses (n=2) are carried out in crimped aluminium pans (2, 10, and 20°C/min, 80mL/min nitrogen). The DSC is calibrated for temperature and heat flow with gallium (Goodfellow, 99.99% Pure), indium (Goodfellow, 99.999% Pure), and tin (NIST SRM 2220).
  • In the schemes and examples below, various reagent symbols and abbreviations have the following meanings:
    DMAc: N,N'-Dimethyl acetamide
    DCHA: Dicyclohexylamine
    MTBE: Methyl-t-butylether
    iPAc: Isopropyl acetate
    DMF: N,N'-Dimethylformamide
    THF: Tetrahydrofuran
    TEA: Triethylamine
    DMSO: Dimethylsulfoxide
    NMP: 1-Methyl-2-pyrrolidinone
    CDI: N N'-Carbonyldiimidazole
    HATU: O-(7-Azabenzotriazol-1-yl)-N,N,N'N'-tetramethyluronium hexafluorophosphate
    EDC: 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride
    HOBt: N-Hydroxybenzotriazole
    NMM: N-methyl morphonline
  • Scheme 1 depicts the reaction of a substituted α-amino acid or its salt with an amine in the presence of a coupling agent, an activator and a base to yield the corresponding α-amino amide product without epimerization of the α-stereocenter.
    Figure imgb0006
  • The following examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless otherwise noted.
  • EXAMPLE 1 (Reference) 4-FLUORO-N-{(1S)-2,2,2-TRIFLUORO-1-[4'-(METHYLSULFONYL)BIPHENYL-4-YL]ETHYL}-L-LEUCINE DICYCLOHEXYLAMINE SALT
  • Figure imgb0007
  • Biphenyl acid (20.74 g) was dissolved in 2-propanol (186 mL) / water (20.7 mL). A solution of N,N-dicyclohexylamine (9.82 mL) in 2-propanol (21 mL) / water (2 mL) was added (∼10% of volume) and the solution was seeded with DCHA salt (10 mg). A heavy seed bed formed and the slurry was let stir at rt for 30 min. Addition of DCHA was continued over 20-30 min. The slurry was let stir at rt overnight and filtered. The filter cake was washed with 2-propanol / water (2 × 30 mL, 10:1) and MTBE (2 × 30 mL). DCHA salt was obtained as a white solid, 24.4 g, 84% yield. 1H NMR (CD3OD) δ 8.07 (d, 2H, J = 8.0), 7.94 (d, 2H, J = 8.0), 7.75 (d, 2H, J = 8.0), 7.61 (d, 2H, J= 8.0), 4.31 (m, 1H), 3.46 (bq, 1H, J= 4), 3.22 (m, 2H), 3.19 (s, 3H), 2.11 (bm, 5H), 1.91 (bm, 5H), 1.75 (bm, 2H), 1.49 (d, 3H, J = 21.6), 1.48 (d, 3H, J = 21.6), 1.35 (m, 9H); 19F NMR (CD3OD) δ - 72.9, - 129.4; mp 209-211 °C, [α]D 20 + 18.7 (c = 0.29, MeOH).
  • EXAMPLE 2 (Reference) N-(1-CYANOCYCLOPROPYL)-4-FLUORO-N 2-{(1S)-2,2,2-TRIFLUORO-1-[4'-(METHYLSULFONYL)BIPHENYL-4-YL]ETHYL}-L-LEUCINAMIDE
  • Figure imgb0008
  • Acid (1.9 g) was dissolved in DMAc (10 mL) and cooled to 0°C. 1-Aminocyclopropane carbonitrile hydrochloride (0.57 g) and HATU (1.85 g) were added. The resulting slurry was stirred for 15 min and DIEA (2.12 mL) was added over 1.5 h. The reaction was aged for 1 h. Water (11.2 mL) was added via dropping funnel over 70 min and the slurry was aged for 1h at 20°C. The mixture was filtered and the filter cake was washed with a solution of DMAc:water (9.4 mL, 1:1.2), water (18.7 mL), 2-propanol (9.3 mL) The batch was dried to yield 1.67 g, 79% yield of the corresponding amide.
  • Amide (2.56 g), was dissolved in THF (30.7 mL) at 30°C. Water (19 mL) was added via dropping funnel. The batch was seeded and aged for 1h at 20°C. Additional water (40.9 mL) was added over 1.5 h and the batch was aged for 16 h. The batch was filtered and washed with water (15 mL). The solids were dried to a constant weight to yield 2.50 g, 97% yield of pure amide. 1H NMR (CD3OD) δ 8.17 (bs, 1H), 8.05 (d, 2H, J= 8.5), 7.96 (d, 2H, J = 8.5), 7.80 (d, 2H, J = 8.0), 7.64 (d, 2H, J= 8.0), 4.43 (m, 1H), 3.55 (ddd, 1H, J = 5.0, 8.5, 8.0), 3.18 (s, 3H), 2.84 (bm, 1H), 2.02 (m, 2H), 1.46 (d, 3H, J = 21.5), 1.43 (d, 3H, J = 22.0), 1.36 (m, 2H), 1.07 (m, 1H), 0.94 (m, 1H); 13C NMR (CD3OD) δ; 19F NMR (CD3OD) δ -73.2, -136.8; IR (cm-1) 3331, 2244, 1687, 1304, 1152; mp 223-224 °C, [α]D 20 + 23.3 (c = 0.53, MeOH).
  • EXAMPLE 3 N-(1-CYANOCYCLOPROPYL)-4-FLUORO-N 2-{(1S)-2,2,2-TRIFLUORO-1-[4'-(METHYLSULFONYL)BIPHENYL-4-YL]ETHYL}-L-LEUCINAMIDE
  • Figure imgb0009
  • A round-bottom flask was charged with biphenyl acid•DCHA salt (76.6 g, 99.2% ee, diastereomeric ratio 342:1) and DMF (590 g). Solid aminocyclopropane carbonitrile•HCl (15.2 g), HOBt•H2O (17.9 g), and EDC•HCl (29.1 g) were all charged forming a white slurry. The batch was then heated to 38-42°C and aged for 5 hours. The batch was then cooled to 20-25°C and held overnight. HPLC analysis showed 99.4% conversion. The batch was heated to 38-42°C and water (375 g) was charged to batch over 2 hours. The batch remained as a slurry throughout the water addition. The batch was then heated to 58-62°C and aged for 1 hour. Following age, water (375 g) was charged over 3 hours, at a rate of 2.1 g/min. The batch was then cooled to 15-25°C and aged overnight. The batch was filtered and washed with 39% DMF in water (2 × 300 g) and 2-propanol (180 g). The solids were dried in the filter at 40-60°C for 24 hours. The desired crude product was isolated as a white solid (57g, 92% yield, 99.4 wt%). A round-bottom flask was charged with crude solid (57 g) and acetone/water solution (324 g, 88/12). The slurry was then heated to 40°C, at which point the batch was in solution, and aged for an hour. Water (46 g) was then charged over 30 minutes. The batch was then seeded (1.7 g, 3.0 wt%), and the batch was aged at 40°C for an hour prior to proceeding with the crystallization. Water (255 g) was charged over 4.5 h. The batch was then cooled to 23°C over 1.5 h, aged for 4 h and filtered. The solids were washed with acetone/water (158 g, 45/55) and water (176 g). The filter cake was dried with nitrogen sweep / vacuum at 55°C. The desired product (57.2 g , 99.9wt%, 99.8A% (enantiomer ND), was obtained in 94.9% yield. 1H NMR (CD3OD) δ 8.17 (bs, 1H), 8.05 (d, 2H, J = 8.5), 7.96 (d, 2H, J = 8.5), 7.80 (d, 2H, J= 8.0), 7.64 (d, 2H, J = 8.0), 4.43 (m, 1H), 3.55 (ddd, 1H, J = 5.0, 8.5, 8.0), 3.18 (s, 3H), 2.84 (bm, 1H), 2.02 (m, 2H), 1.46 (d, 3H, J= 21.5), 1.43 (d, 3H, J= 22.0), 1.36 (m, 2H), 1.07 (m, 1H), 0.94 (m, 1H); 13C NMR (CD3OD) δ; 19F NMR (CD3OD) δ -73.2, -136.8; IR (cm-1) 3331, 2244, 1687, 1304, 1152; mp 223-224 °C, [α]D 20 + 23.3 (c = 0.53, MeOH).

Claims (5)

  1. A process for preparing a compound of formula I:
    Figure imgb0010
    comprising amidating a salt of formula IIA or an acid of formula IIB
    Figure imgb0011
    with 1-aminocyclopropane carbonitrile, in the presence of a coupling agent which is EDC, a base and a solvent; wherein R1 is (2-fluoro, 2-methyl) propyl;
    R2 is trifluoromethyl;
    R3 is SO2 CH3;
    X is a tertiary amine, a secondary amine or a metal salt; and
    m is an integer from zero to two.
  2. The process of Claim 1 wherein the base is N-methyl morpholine, TEA, N-ethyldiisopropylamine, 2,6-lutidine, 2,4,6 collidine or 1-methylpiperidine.
  3. The process of Claim 1 or 2 wherein the solvent is DMF, DMAc, NMP, acetonitrile, THF or DMSO.
  4. The process of Claim 1, 2 or 3 which also comprises an activating agent which is N-hydroxy succinimide, 2-hydroxypyridine, N-hydroxyphthalimide, CDI or HOBt.
  5. The process of Claim 4 wherein the activating agent is HOBt; the base is N-methyl morpholine; and the solvent is DMF.
EP08733702.8A 2007-04-02 2008-03-31 Amidation process for the preparation of cathepsin k inhibitors Not-in-force EP2144871B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92132107P 2007-04-02 2007-04-02
PCT/CA2008/000605 WO2008119176A1 (en) 2007-04-02 2008-03-31 Amidation process for the preparation of cathepsin k inhibitors

Publications (3)

Publication Number Publication Date
EP2144871A1 EP2144871A1 (en) 2010-01-20
EP2144871A4 EP2144871A4 (en) 2011-11-23
EP2144871B1 true EP2144871B1 (en) 2014-06-25

Family

ID=39807759

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08733702.8A Not-in-force EP2144871B1 (en) 2007-04-02 2008-03-31 Amidation process for the preparation of cathepsin k inhibitors

Country Status (7)

Country Link
US (1) US8273913B2 (en)
EP (1) EP2144871B1 (en)
JP (1) JP5364695B2 (en)
CN (1) CN101668736B (en)
AU (1) AU2008234380B2 (en)
CA (1) CA2682622A1 (en)
WO (1) WO2008119176A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2681188A4 (en) * 2011-03-02 2015-04-15 Merck Sharp & Dohme AMIDATION METHOD
CZ2014941A3 (en) 2014-12-19 2016-06-29 Zentiva, K.S. Preparation process of extremely pure intermediate for odanacatib synthesis
US10472345B2 (en) 2016-02-04 2019-11-12 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
HRP20040800B1 (en) * 2002-03-05 2012-11-30 Merck Frosst Canada & Co Axys Cathepsin cysteine protease inhibitors
CA2535359A1 (en) 2003-08-21 2005-03-03 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
EP1660436A4 (en) * 2003-08-27 2006-11-22 Merck Frosst Canada Ltd INHIBITORS OF CATHEPSINE
KR20070061877A (en) 2004-09-17 2007-06-14 바이엘 쉐링 파마 악티엔게젤샤프트 Methods and Intermediates for the Preparation of Cysteine Protease Inhibitors

Also Published As

Publication number Publication date
EP2144871A1 (en) 2010-01-20
CN101668736B (en) 2013-06-12
CN101668736A (en) 2010-03-10
EP2144871A4 (en) 2011-11-23
JP5364695B2 (en) 2013-12-11
US20100130782A1 (en) 2010-05-27
AU2008234380B2 (en) 2013-01-24
CA2682622A1 (en) 2008-10-09
US8273913B2 (en) 2012-09-25
WO2008119176A1 (en) 2008-10-09
JP2010523500A (en) 2010-07-15
AU2008234380A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
JP6985367B2 (en) New compounds and methods
JP6873053B2 (en) Method for Producing Protein Deacetylation Inhibitor
JP2024503855A (en) Method for synthesizing aminopyrimidine-based FAK inhibitor compounds
EP2144871B1 (en) Amidation process for the preparation of cathepsin k inhibitors
EP3280721B1 (en) Process for preparation of nitrogen mustard derivatives
JP2019147763A (en) Manufacturing method of proline amide compound
CN1188475A (en) Guanidine derivatives, their intermediates and their products
US20170066715A1 (en) Amidation process
TWI545114B (en) Method for preparing biphenyl imidazole compound
US8278484B2 (en) Process for preparing a benzoylbenzeneacetamide derivative
WO2009090663A1 (en) Novel crystalline polymorph of armodafinil and an improved process for preparation thereof
JP7693921B2 (en) Method for producing prolinamide compound
JP2010083888A (en) Method for preparing azelnidipine crystal
EP4349847A1 (en) Process and intermediates for preparation of omaveloxolone and salts thereof
HK1250732B (en) Process for preparation of nitrogen mustard derivatives
CN108727212A (en) A kind of synthesis of Mirabegron intermediate (R) -2- hydroxy-ns-(4- nitrophenethyls) -2- phenyl-acetamides
NZ736564B2 (en) Process for preparation of nitrogen mustard derivatives
GB2552697A (en) Process for the preparation of boscalid
JP2005247824A (en) Method for producing 3-acylaminobenzofuran-2-carboxylic acid derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK CANADA INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20111024

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/04 20060101ALI20111019BHEP

Ipc: C07C 317/32 20060101ALI20111019BHEP

Ipc: C07B 43/06 20060101ALI20111019BHEP

Ipc: A61K 31/277 20060101ALI20111019BHEP

Ipc: C07C 315/04 20060101AFI20111019BHEP

Ipc: A61P 19/10 20060101ALI20111019BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK CANADA INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK CANADA INC.

17Q First examination report despatched

Effective date: 20130423

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140204

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 674587

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008032977

Country of ref document: DE

Effective date: 20140807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140925

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140926

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 674587

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140625

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20140625

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141027

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141025

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008032977

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20150326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20170222

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20080331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20170223

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20170331

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602008032977

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331